SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 6.6% Beneficial Ownership in Beam Therapeutics Inc.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Beam Therapeutics Inc. as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, collectively beneficially own 5,439,333.05 shares of Beam Therapeutics Inc. Common Stock.
• This aggregate amount represents 6.6% of the total outstanding Common Stock of Beam Therapeutics Inc.
• FMR LLC holds sole voting power over 5,434,746.00 shares and sole dispositive power over 5,439,333.05 shares.
• Abigail P. Johnson, who is a Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same 5,439,333.05 shares, with sole dispositive power over them.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of Beam Therapeutics Inc.
• Several subsidiaries and affiliates of FMR LLC, including Crosby Advisors LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, IMPRESA MANAGEMENT LLC, and Strategic Advisers LLC, are identified as entities that beneficially own shares.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC, representing 49% of its voting power, and may be deemed to form a controlling group with respect to FMR LLC.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. The certification explicitly states no intent to influence control, maintaining a neutral stance.

Positives

• The disclosure of a significant ownership stake by a major institutional investor like FMR LLC can signal confidence in Beam Therapeutics Inc.'s long-term prospects.
• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control, which may reduce concerns about potential activist investor actions.

Negatives

• The document does not contain information that would typically be categorized as negative, as it is a factual disclosure of ownership.

Risks

• The document does not explicitly detail company-specific risks beyond the inherent nature of equity ownership.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of a significant ownership stake by a major asset manager in a publicly traded biotechnology company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence investor perception and potentially stock liquidity.
• Company Management: Awareness of a large, passive institutional holder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Beneficial Ownership, SEC Filing, Schedule 13G, FMR LLC, Abigail P. Johnson, Beam Therapeutics Inc., Common Stock, Institutional Investor, Equity Stake, Disclosure